Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B in a Non- Bleeding State

Inclusion Criteria: * Age 18-55 years and congenital haemophilia A or B male with severe FVIII or FX deficiency +/-inhibitors * Age between 3-12 years and congenital haemophilia A or B male with record of inhibitors Exclusion Criteria: * Known hypersensitivity to activated recombinant human factor VII or any of its components * Known clinical relevant coagulation diseases or insufficiencies other than congenital haemophilia * Clinical manifestation of HIV (human immunodeficiency virus) and/or protease inhibitor treatment * Clinical manifestation of active/recent bleeding * Administration of coagulation factor preparations within 24 hours of NovoSeven trial product dose administration * Body Mass Index (BMI) outside normal range * Known abuse of elicit drugs and/or alcohol * Renal insufficiency * Hepatic disease * Cardiovascular disease * Any disease or condition which, judged by the Investigator, could imply a potential hazard to the patient, interfere with the trial participation or trial outcome